Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Pour L, Szarejko M, Bila J, Schjesvold FH, Spicka I, Maisnar V, Jurczyszyn A, Grudeva-Popova Z, Hájek R, Usenko G, Thuresson M, Norin S, Jarefors S, Bakker NA, Richardson PG, Mateos MV.
Pour L, et al. Among authors: grudeva popova z.
Haematologica. 2024 Mar 1;109(3):895-905. doi: 10.3324/haematol.2023.283509.
Haematologica. 2024.
PMID: 37646660
Free PMC article.
Clinical Trial.